Indian Pharma PCD Franchise: Factors Fueling its Growth

1
Welcome To Balaji Biotech
2
Indian Pharma PCD Franchise Factors Fueling its
Growth
The global pharma market is going through a
significant transformation, especially for us in
the Indian sector. As the developed markets face
a slowdown, it is the emerging markets that are
emerging as a viable alternative. This is good
news for Indian companies that are uniquely
poised to take the lead position in the decade to
come.
3
Closely linked with the success story of the
bigger companies is the role of other smaller
players, such as pharma pcd franchises. In this
growth story it is part of other emerging markets
like Brazil, Russia and China. But there are
reasons why many investors are upbeat over
Indias chances against its competitors. This is
because Indian firms offer certain unique
advantages.   The factors behind the Indian
phrama sectors growth lies in the organic nature
of its development.
4
Presence of branded drugs Although Indian is
seen as the leader in generic drugs worldwide,
the Indian market is today dominated by branded
drugs. According to the latest McKinsey report,
70-80 percent of the market is dominated by this
sector. This is great news because even through
generic drugs drive our volumes, it is the
branded drugs that get the big revenue. This
also gives us an edge internationally. It
exhibits Indian companies', including the pharma
pcd franchises', ability to lead in both sectors.
It shows that unlike its competitors Indian
firms' expertise does not lie solely in creating
cheaper knock-off of more expensive drugs.
5
Strong local companies When we closely look at
the rise of the pharma sector in many other
countries, we find one rather unwelcome data. The
rise of pharma in emerging market is actually
fueled by the top international firms who were
creating their second base away front the slowly
declining developed market. So, even though we
were seeing an emergence of these markets, much
of the benefit was going to the already
established players. This is where India
differs significantly. Unlike many other
developing nation, India has a core set of strong
business houses, entrepreneurs and a history in
pharma research and industry. There are industry
leaders who have coped with daunting odds of
government red tape and low investment, while
trying to develop and sell medicines to a fairly
low value market. What this has given us is a
strong backbone of local investments, workforce
and market rules. It has also reduced our
dependence on international firms, keeping the
growth and revenues within the local industry.
6
Cost benefit Like a lot of emerging markets the
Indian pharma sector has also benefitted from the
surging costs of drugs and medical care in
developed countries. The truth is that many drugs
are overcharged by massive margins in these
countries. Even accounting for their RD
investment, the drugs, many of which are
lifesaving, are too steeply priced. Indian
drugs, on the other hand, are significantly
cheaper. Local and inter nation competition has
further kept the costs fairly low. In many pooper
countries like many of the African countries,
Indian companies are the leaders. The result is
that Indian drug sales lead in volume with a
dominance over international markets.
7
Strong medical infrastructure Unlike many of the
emerging markets, the Indian pharma pcd franchise
success is also backed by a strong medical
infrastructure. This includes leading hospital,
patient care facilities, accomplished doctors,
RD facilities and established medical colleges
that ensure a professional backbone to the
medical industry. In other words, the Indian
pharma story has not grown in isolation. It has
grown as a response to rising health
consciousness, local demand for better medicines
and competition. This infrastructure gives the
industry a much needed foundation and an organic
growth pattern one that is essential to ensure
sustainable growth and development.
8
Rising demand The strongest factor in the growth
of the Indian pharma sector is its organic
nature. It has grown because of local demands and
requirement. As the prevalence of chronic
diseases becomes more common, the demand for
treatment and cure has also gone up. This has
fueled investment and RD the two essential
factors in the growth of any pharma industry.
  Conclusion   While the global slowdown may
have given it a fillip, the Indian pharma pcd
franchise story no flash in the pan. Its current
leading position is the result of a strong local
demand, infrastructure and emerging competitors.
9
Contact Details
Address Balaji Biotech Rajeev Agrawal
(Proprietor)No. 8, Sahjanand Estate, Behind
Lalji Mulji Transport, S.G. Highway, Sarkhej
Ahmedabad - 382210, Gujarat, India
Contact Number Mobile Number (91)-9825845426,
(91)-8460000199 Email Address Email
balajibiotech2004_at_gmail.com
10
THANK YOU